Related Experiment Videos
Insulin can modulate MCF-7 cell response to paclitaxel
Antonella Miglietta1, Maria Luisa Panno, Francesca Bozzo
1Department of Experimental Medicine and Oncology, University of Torino, Corso Raffaello 30, Torino 10125, Italy. antonella.miglietta@unito.it
Cancer Letters
|May 26, 2004
Summary
Insulin affects how breast cancer cells respond to paclitaxel, potentially impacting treatment resistance. This study investigated insulin
Area of Science:
- Endocrinology
- Cancer Biology
- Pharmacology
Background:
- Insulin regulates cellular metabolism via receptor tyrosine kinases.
- Insulin influences breast cancer cell proliferation.
- Paclitaxel is a chemotherapy agent targeting microtubules.
Purpose of the Study:
- To investigate insulin's effect on paclitaxel-mediated biological activity in human breast cancer cells.
- To determine if insulin interferes with paclitaxel's action, alone or in combination.
- To explore insulin's role in paclitaxel resistance.
Main Methods:
- Cultured MCF-7 human breast cancer cells.
- Administered insulin and paclitaxel separately and in combination.
- Assessed effects on cell microtubule reorganization.
- Evaluated MCF-7 cell sensitivity to paclitaxel.
- Analyzed MAPK pathway activation, Raf-1, and p53 expression.
Main Results:
- Insulin modulated paclitaxel-mediated microtubule reorganization in MCF-7 cells.
- Insulin influenced MCF-7 cell sensitivity to paclitaxel.
- Combined insulin and paclitaxel administration affected the MAPK pathway, Raf-1 activation, and p53 expression levels.
Conclusions:
- Insulin appears to modulate the response of MCF-7 breast cancer cells to paclitaxel.
- Elevated insulin levels may contribute to tumor cell resistance to paclitaxel.
- Further research is warranted to elucidate the clinical implications of insulin's role in breast cancer therapy.